{
  "id": 8164145,
  "title": "Jula Inrig, Travere R&D EVP, sells $2.78m in shares",
  "url": "https://urgent.news/2026/09/18/jula-inrig-travere-r-d-evp-sells-2-78m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T03:35:41.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/jula-inrig-travere-rd-evp-sells-278m-in-shares-93CH-4906653"
  },
  "original_language": "en",
  "account": "Jula Inrig, Executive Vice President, Head of Research & Development and Chief Medical Officer at Travere Therapeutics, Inc. (TVTX), sold 44,674 shares of common stock on September 15, 2026, for $2,785,020. The sale occurred at prices ranging from $62.0167 to $65.31. Before selling, Inrig acquired 32,395 shares by exercising employee stock options at $8.93 per share. These sales were executed according to a Rule 10b5-1 trading plan adopted on June 16, 2026. The transactions comprised various portions: 25,390 shares at an average price of $62.0167, 17,284 shares at $62.6242, 1,600 shares at $63.685, and 400 shares at $65.31. Following these sales, Inrig beneficially owns 100,491 shares of Travere Therapeutics common stock. Travere Therapeutics reported a Q2 revenue of $169.6 million, exceeding expectations of $160.66 million. This increase was primarily due to a 96% sales rise for their kidney drug FILSPARI, which generated $141.1 million in revenue. The company also earned $8.2 million from licensing and collaboration agreements. Stifel raised its price target for Travere Therapeutics to $62, maintaining a Hold rating. The company concluded the quarter with $489.2 million in cash, equivalents, and marketable securities.",
  "summary": null,
  "key_points": [
    "Jula Inrig sold 44,674 shares of Travere Therapeutics at $2.78m",
    "Sales executed per Rule 10b5-1 plan on 15 September 2026",
    "FILSPARI drug drove Q2 revenue increase to $169.6m"
  ],
  "editors_take": "The sale of $2.78 million in shares by Travere R&D EVP Jula Inrig, executed under a pre-set trading plan, suggests a managed approach to personal holdings rather than a change in confidence in the company's prospects.",
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Paysign EVP, operations Joan Herman sells $716,899 in shares",
        "url": "https://urgent.news/2026/09/18/paysign-evp-operations-joan-herman-sells-716-899-in-shares",
        "published": "2026-09-18T02:45:54.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}